Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism

With the aim to expand the randomized controlled trial evidence of cinacalcet treatment to the unselected, general chronic kidney disease (CKD) population we analysed a large inception cohort of CKD patients in the region of Stockholm, Sweden 2006–2012 (both non-dialysis, dialysis and transplanted)...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marie, Methven, Shona, Gasparini, Alessandro, Barany, Peter, Birnie, Kate, MacNeill, Stephanie, May, Margaret T., Caskey, Fergus J., Carrero, Juan-Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/
https://www.ncbi.nlm.nih.gov/pubmed/29391567
http://dx.doi.org/10.1038/s41598-018-20552-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/
https://www.ncbi.nlm.nih.gov/pubmed/29391567
http://dx.doi.org/10.1038/s41598-018-20552-5

Ejemplares similares